Showing 2361-2370 of 5696 results for "".
- Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMDhttps://modernod.com/news/adverum-biotechnologies-granted-priority-medicines-prime-designation-by-european-medicines-agency-for-advm-022-in-wet-amd/2480943/Adverum Biotechnologies announced that the European Medicines Agency (EMA) has granted ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related macular degeneration (AMD). Adverum’s lead gene therapy candidate, ADVM-022, is a one-time, intr
- EssilorLuxottica Chairman Leonardo Del Vecchio Passes Away at Age 87https://modernod.com/news/essilorluxottica-chairman-leonardo-del-vecchio-passes-away-at-age-87/2480931/Italian fashion icon Leonardo Del Vecchio, chairman of EssilorLuxottica, passed away at the age of 87, the company announced Monday. "The company expresses its deepest condolences to the family and to the global employee community for this enormous loss. The Board will m
- The Vision Council Announces that Version 3.13 of the Data Communication Standard is Now Availablehttps://modernod.com/news/the-vision-council-announces-that-version-313-of-the-data-communication-standard-is-now-available/2480893/The Vision Council announced the publication of Version 3.13 of the Standard for Data Communications. The standard, which is used by manufacturers of optical lab equipment and producers of software used in optical labs, was developed by The Vision Council’s Lens Proce
- Nicox Now Expects Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial in November 2022https://modernod.com/news/nicox-now-expects-topline-results-from-ncx-470-mont-blanc-phase-3-glaucoma-trial-in-november-2022/2480892/Nicox SA announced that it has closed screening for additional patients in its phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension. Therefore, the company now expects
- Holland Foundation for Sight Restoration Appoints Kila Hanrahan Director of Developmenthttps://modernod.com/news/holland-foundation-for-sight-restoration-appoints-kila-hanrahan-director-of-development/2480875/Kila Hanrahan, who has more than a decade experience in fundraising initiatives, has joined the Holland Foundation for Sight Restoration as Director of Development. “We are very excited to have Kila joining the Holland Foundation as the first employee,” said Holland Fo
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101https://modernod.com/news/qlaris-bio-reports-phase-2-clinical-trial-results-demonstrating-favorable-safety-and-tolerability-profile-and-positive-efficacy-signal-for-qls-101/2480871/Qlaris Bio announced results from QC-201, a first-in-human, phase 2 clinical trial of QLS-101, the company’s investigational therapy for lowering IOP in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evi
- Tarsus Presents New Findings From Two Studies That Demonstrate the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meetinghttps://modernod.com/news/tarsus-presents-new-findings-from-two-studies-that-demonstrate-the-impact-of-demodex-blepharitis-at-the-arvo-2022-annual-meeting/2480847/Tarsus Pharmaceuticals, Inc. presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on the coexisting bacterial burden for patients with
- Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technologyhttps://modernod.com/news/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatility-of-suprachoroidal-delivery-technology/2480845/Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalm
- Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03https://modernod.com/news/bausch-lomb-presents-data-from-second-pivotal-phase-3-trial-of-investigational-treatment-nov03-at-arvo/2480837/Bausch + Lomb and Novaliq announced that data from the second pivotal phase 3 trial (MOJAVE) of investigational treatment NOV03 (perfluorohexyloctane) were presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. NOV03 is being investigated as a first-in-c
- Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-detailed-18-month-results-from-phase-3-derby-and-oaks-studies-of-pegcetacoplan-for-geographic-atrophy-ga-at-arvo/2480830/Apellis Pharmaceuticals announced detailed, longer-term data from the phase 3 DERBY and OAKS studies of intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Monthly and